Ulcerative colitis-driven gut dysbiosis exacerbates periodontal bone loss through the gut-oral axis /Th17/Treg imbalance

Ulcerative colitis (UC) and gum disease (periodontitis) are both driven by imbalanced microbial communities and chronic inflammation, and they frequently occur together in patients — but until now, whether one directly causes the other to worsen has been unclear. This study used mouse models to show that UC can actively make periodontal bone loss roughly twice as severe, not just by coincidence but through a chain of biological events originating in the gut. The researchers identified that UC disrupts the gut microbiome by depleting beneficial bacteria (particularly Firmicutes) and expanding harmful ones (Bacteroides), while also reducing protective short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate by 35–60%. This microbial shift damages the gut barrier, allowing inflammatory signals to spill into the bloodstream, tip the immune system toward a pro-inflammatory Th17 state at the expense of regulatory Treg cells, and ultimately accelerate the bone-destroying process in the jaw. Crucially, transplanting gut bacteria from UC mice into healthy periodontitis-prone mice reproduced all these harmful effects, while transplanting bacteria from healthy donors protected against them — proving the gut microbiome is a transmissible causal driver, not a bystander. Two bacterial genera, Parabacteroides and Muribaculum, emerged as key species whose decline tracked closely with reduced SCFA levels and increased inflammatory gene activity. The findings suggest that restoring SCFA-producing gut bacteria — through probiotics, dietary change, or direct SCFA supplementation — could be a therapeutic strategy for patients who have both conditions.

• UC (modeled by DSS-colitis) approximately doubled alveolar bone loss in mice with ligature-induced periodontitis compared to periodontitis alone, alongside heightened systemic inflammation, oxidative stress, and osteoclast activity.
• 16S rRNA sequencing and LC-MS metabolomics showed UC mice had enriched oral pathogens, depleted gut Firmicutes, expanded Bacteroides, and suppressed amino-acid and bile-acid biosynthesis pathways.
• GC-MS quantification revealed 35–60% reductions in fecal SCFAs (acetate, propionate, butyrate) in UC mice; keystone taxa Parabacteroides and Muribaculum inversely correlated with both SCFA levels and host inflammatory gene expression.
• Fecal microbiota transplantation (FMT) from DSS-colitis donors into antibiotic-pretreated periodontitis-prone mice replicated aggravated alveolar bone loss, systemic inflammation, gut-barrier leakage, and Th17/Treg imbalance — directly demonstrating transmissible causality.
• FMT from healthy donors into the same antibiotic-pretreated periodontitis-prone recipients conferred protection against bone loss and immune dysregulation, providing a positive-control proof of the microbiome's causal role.

The study used a dual mouse model combining ligature-induced periodontitis with DSS (dextran sodium sulfate)-induced colitis to mimic human UC-periodontitis comorbidity. Gut and oral microbiome profiling was performed by 16S rRNA amplicon sequencing; metabolomic characterization of fecal SCFAs used GC-MS, and broader metabolite profiling used LC-MS. FMT experiments involved antibiotic pretreatment of recipient periodontitis-prone mice followed by gavage with either DSS-donor or healthy-donor fecal material, with subsequent assessment of bone loss (likely micro-CT), barrier integrity, immune cell populations (Th17/Treg), osteoclast markers, and inflammatory cytokines. Sample sizes and precise follow-up duration are not specified in the abstract but are consistent with standard murine colitis-periodontitis experimental windows of 4–8 weeks.

This is an entirely preclinical murine study, and the degree to which DSS-colitis and ligature-induced periodontitis faithfully replicate the chronic, heterogeneous course of human UC and periodontitis remains uncertain, limiting direct clinical translation. The FMT experiments establish that the gut microbiome is causally sufficient to worsen bone loss, but do not isolate which specific bacterial species, metabolites, or immune signals are individually necessary — mechanistic dissection with germ-free or gnotobiotic models would help. The study does not report whether restoring SCFAs (via supplementation rather than FMT) alone is sufficient to reverse established bone loss, which is the key therapeutic question. Human epidemiological or interventional data confirming that gut dysbiosis precedes or predicts periodontal severity in UC patients would be needed before clinical strategies can be designed.

This article extends [§150], which provides the theoretical framework on gut microbiota's role in immune-related inflammatory diseases — the current study exemplifies that framework with granular mechanistic data on how UC-driven dysbiosis propagates systemic Th17/Treg imbalance and tissue destruction at a distal mucosal site. It parallels [§120], which also demonstrates that specific gut commensals (Eubacterium rectale) modulate inflammatory pathways (via metabolic reprogramming) in IBD contexts, reinforcing the broader principle that keystone taxa and their metabolic outputs are critical disease modulators — here Parabacteroides and Muribaculum occupy an analogous keystone role through SCFA production. The study further parallels [§146], which shows that a bile-acid metabolite (lithocholic acid) mediates macrophage reprogramming to alleviate UC, since the current article similarly implicates bile-acid biosynthesis suppression as part of the dysbiosis-driven pathogenic cascade — together these articles suggest complementary metabolic axes (SCFAs and bile acids) through which gut microbiota control systemic inflammatory tone. The SCFA-depletion finding also contextually aligns with [§155], which examines how gut barrier integrity is modulated by microbial interventions, given that SCFA loss in the current study is mechanistically linked to epithelial barrier erosion and downstream systemic immune activation.

• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Both identify specific gut commensal taxa whose metabolic outputs (glutamine metabolism via GLS2/NF-κB vs. SCFAs via Parabacteroides/Muribaculum) are causally linked to IBD-associated inflammatory control — comparing them reveals complementary therapeutic targets within gut microbial metabolism.
• Intermittent fasting alleviates ulcerative colitis via lithocholic acid-mediated macrophage reprogramming
  Both study UC in mouse models and identify gut-derived metabolites (lithocholic acid vs. SCFAs) as key immunomodulatory signals, but via distinct pathways (macrophage reprogramming vs. Th17/Treg balance), making them useful paired reads on metabolite-immune crosstalk in colitis.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Directly relevant comparator on gut barrier function: this article examines how a probiotic (Saccharomyces boulardii) restores intestinal barrier integrity, the same barrier whose erosion the current study identifies as the mechanistic bridge between UC dysbiosis and systemic/periodontal inflammation.
• Editorial: The role of gut microbiota in immune-related inflammatory diseases
  This editorial synthesizes the immunological role of gut microbiota across inflammatory diseases and provides the conceptual scaffold the current study operationalizes — reading both together clarifies how the gut-oral axis findings fit into the wider field of microbiota-immunity crosstalk.
• Anti-inflammatory and gut microbiota-modulating effects of a novel mannan from Scilla scilloides on DSS-induced colitis in mice
  Both use DSS-colitis mouse models and 16S rRNA-based microbiome profiling to evaluate dysbiosis and barrier dysfunction, allowing methodological comparison of how gut community shifts are characterized and interpreted across different experimental interventions.